The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. - Wikidata - wikimedia - TriplyDB

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

http://www.wikidata.org/entity/Q36537388

about

Teriparatide for osteoporosis: importance of the full course New insights into treatment of osteoporosis in postmenopausal women Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Osteoporosis Treatment: When to Discontinue and When to Re-start Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis Management of Hypoparathyroidism: Present and Future.Osteosarcoma Overview.Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival.Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy.Romosozumab for the treatment of osteoporosis.Parathyroid hormone therapy for hypoparathyroidism Use of parathyroid hormone in hypoparathyroidism.PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.Management of severe osteoporosis.Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database Living-donor parathyroid allotransplantation for therapy-refractory postsurgical persistent hypoparathyroidism in a nontransplant recipient - three year results: a case report.Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.Inflammation, fracture and bone repair.Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts PTH prevents the adverse effects of focal radiation on bone architecture in young rats Osteoporosis - a current view of pharmacological prevention and treatment Predictors of teriparatide treatment failure in patients with low bone mass.Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis.TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review).The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication.Review of Hypoparathyroidism.Osteoporosis and treatments in Japan: management for preventing subsequent fractures.Recombinant hormones in osteoporosis.Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort.Osteoporosis after stem cell transplantation.Underweight, overweight, and pediatric bone fragility: impact and management.Management of osteoporosis of the oldest old.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.

P2860

Q26768410-0C5FEDB7-A000-4C89-AA8E-2F21F3649DA0 Q26777910-7CFFD0C3-D5F2-4713-A823-0F9D818A8841 Q26782621-066003A6-53FE-439E-A831-53960ADAA2D0 Q26858980-529A3A8A-4EBD-4F15-8704-C491643326D0 Q27024513-F9C9DED9-B8DD-466A-8505-4B8C62758577 Q33570607-7A533C0E-09CE-4D23-9D0A-8EDAB66F43AD Q33725511-9DA15530-F571-4F11-9EAE-2DCF4A8009C0 Q33812106-F2C3F3BF-0E46-46AB-844A-A37BF2D5668F Q34132998-5145C1FB-30BF-40B6-9151-53F86418D4B6 Q34575759-72207341-7462-4ACD-90F8-63EA60C51BE9 Q34680463-ED9C2B72-0467-4B5A-987C-ADD69A0366FA Q35014795-79A1EA76-2C98-44F4-9552-8C380D25C892 Q35043115-EAF74240-10D8-4EDE-A18D-A3CF226ADEB0 Q35100381-57F2C6F0-77A8-4A58-A340-15B378BF0B5A Q35694436-6D504A11-C18F-4C2A-B5D8-6839CDAC377A Q35852252-DC830EF7-9DEB-44EE-9CBE-41BB75F893BE Q36058859-C2DC8C6F-0FCA-4F1E-B1C8-44C85D9668BE Q36069376-41A3759E-CB12-4EA8-9E18-4BA13C39F1E5 Q36094415-843BA34A-4AC8-4A86-AD88-61525B411CBC Q36127944-49ADFDFE-EB1E-4328-A756-4B70CBBE8832 Q36803719-A87E05A5-18AD-410C-B4C7-65DBD1B02420 Q36817240-B9CDA57C-750C-488B-89DF-3D520561BAC7 Q36852779-FD062683-1F87-4681-B531-7E286278FA9C Q36920155-68E2179B-ABC7-45DA-8A34-44739106119A Q36939677-5F8CB709-4240-40B2-82AA-9A1BAFEA44E0 Q37051656-BF2F5EB3-2654-4A04-8C60-730F8D6E06B2 Q37082771-F10E6D27-8EE0-4E2E-B551-17B400306405 Q37124509-DBF275D4-5233-4D28-9683-DE2789F6242A Q37134482-591595A1-7647-43B7-8DA4-DD9506D9D94A Q37211620-91AEA8E2-C727-49FA-8E7C-1447E232CE2A Q37255459-DF26A9E7-CE49-4209-A8D3-7D134FFAC207 Q37357435-6BC23C1C-E4C9-42C1-B768-6AC1E1DB0BFA Q37587224-0F671638-E784-478D-90C2-084DB01BE638 Q38093784-624B6D40-AB8B-4A87-B30F-093C7A7C6B56 Q38104374-04B3EA4E-2E3B-4458-B301-31E14202CF0A Q38126878-2474ABBF-F9A7-4C82-A123-B25563115BD6 Q38160758-6B2AB6AD-2375-4F64-8FF9-00463C66E0A4 Q38225482-DE41D6C0-B9B7-48BE-A66E-0B9F93AE175F Q38229503-3E963913-85F0-448A-9F9C-1511E4BD49FB Q38241347-AB5AA9DA-A364-4784-8884-7DB31CA40822

P2860

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

http://www.wikidata.org/entity/Q36537388

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The US postmarketing surveilla ...... ndings from the first 7 years.

@ast

The US postmarketing surveilla ...... ndings from the first 7 years.

@en

type

label

The US postmarketing surveilla ...... ndings from the first 7 years.

@ast

The US postmarketing surveilla ...... ndings from the first 7 years.

@en

prefLabel

The US postmarketing surveilla ...... ndings from the first 7 years.

@ast

The US postmarketing surveilla ...... ndings from the first 7 years.

@en

P1433

Q36537388-5B0B6C35-7136-4FFF-921E-5B24FBC5F322

P1476

Q36537388-C2BBAA0A-57F0-4A58-B930-FE094F72CF0A

P2093

Q36537388-5C4701F7-3074-4DC5-AF3F-6072CFA7535B

Q36537388-5E473F91-6ADC-4BF3-A02E-A871029F3E4B

Q36537388-6AAA8105-071F-4FA4-B05A-451420EC20DE

Q36537388-CB6DA36A-B400-491B-AB44-76ED1F9A8BDC

Q36537388-D67F2F4E-74CF-4CA1-A0F1-DF7A28EC3378

Q36537388-F88B1900-FD4A-4F86-BE38-7C6615BD0445

P2860

Q36537388-21614FCC-CE8A-44C2-AD15-29B170878D33

Q36537388-334BE51C-3764-4636-8E46-2E1282550D86

Q36537388-60954523-D770-4174-9FBE-7345FF3D5500

Q36537388-6E380E25-2C5C-4C1E-92B2-016A85CEA7E6

Q36537388-96C7DF83-30E1-4BF8-A748-7AEA79E2600E

Q36537388-E2B12F7B-5AA1-43C9-AD4E-EA30BEE98602

Q36537388-E346897F-09FB-477E-9DE8-2E3CC6F40BBE

Q36537388-E9B336A3-F59D-4E09-9DE1-1A749FCE6217

Q36537388-F94D91C7-F333-4244-B630-8E8310C35946

P304

Q36537388-6AE76E77-9D55-4AA1-99C8-A0657B70EC15

P31

Q36537388-D908A296-402D-4721-8BB4-AAE658AE4E81

P356

Q36537388-6D29B04C-0BFF-4FFD-BD29-011C1DAC432E

P433

Q36537388-B0752595-9FAF-4339-B166-57D351C25913

P478

Q36537388-5FAF408C-B749-466C-B572-A3841CCC8F85

P50

Q36537388-DEDBCA83-C6BF-4351-B7CC-66A8F2ED23E0

P577

Q36537388-0FA3940B-55DB-48E9-85E5-2E0F1E096D54

P5875

Q36537388-C6441DA8-9EEC-4F57-8FBC-2525707E0705

P698

Q36537388-316ECC66-FB11-4494-A17D-522E1DDCBA2D

P932

Q36537388-DF7992BA-3113-44E6-B806-11869E5EF49F

P356

P1433

Journal of Bone and Mineral Research

P1476

The US postmarketing surveilla ...... indings from the first 7 years

@en

P2093

Alicia W Gilsenan

http://www.w3.org/2001/XMLSchema#string

Beth H Mann

http://www.w3.org/2001/XMLSchema#string

Beth Sherrill

http://www.w3.org/2001/XMLSchema#string

Daniel Masica

http://www.w3.org/2001/XMLSchema#string

Elizabeth B Andrews

http://www.w3.org/2001/XMLSchema#string

Yun Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

An assessment of bone fluoride and osteosarcoma.

Osteosarcoma over the age of forty.

International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.

Using epidemiology and genomics to understand osteosarcoma etiology.

Of mice and men: divergent risks of teriparatide-induced osteosarcoma.

Occupational factors and risk of adult bone sarcomas: a multicentric case-control study in Europe.

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.

P304

2429-2437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.1768

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Kirk D. Midkiff

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230880376

http://www.w3.org/2001/XMLSchema#string

P698

22991313

http://www.w3.org/2001/XMLSchema#string

P932

3546381

http://www.w3.org/2001/XMLSchema#string